ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab - תרכיז להכנת תמיסה לאינפוזיה - pertuzumab 420 mg / 14 ml - pertuzumab - pertuzumab - perjeta is indicated in combination with trastuzumab and docetaxel for the treatment of patients with her2 positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - obinutuzumab - תרכיז להכנת תמיסה לאינפוזיה - obinutuzumab 1000 mg / 40 ml - obinutuzumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה להזרקה - trastuzumab 600 mg / 5 ml - trastuzumab

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - pembrolizumab - תרכיז להכנת תמיסה לאינפוזיה - pembrolizumab 25 mg/ml - pembrolizumab

ישראל - עברית - Ministry of Health

amgen europe b.v. - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab

ישראל - עברית - Ministry of Health

j-c health care ltd - amivantamab - תרכיז להכנת תמיסה לאינפוזיה - amivantamab 350 mg / 7.0 ml - amivantamab

ישראל - עברית - Ministry of Health

kamada ltd, israel - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab